Astellas

News

Astellas cuts $5.9bn deal to buy Iveric Bio

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector,

News

FDA clears Keytruda/Padcev regimen for bladder cancer

The combination of Merck & Co’s checkpoint inhibitor Keytruda and Seagen/Astellas’ antibody-drug conjugate Padcev has been approved by the FDA as an alternative to che

News

Astellas GLOWing as Claudin drug aces gastric cancer trial

Pair of positive phase 3 studies means company will file for approval of zolbetuximab soon.

News

Japanese pharmas sign up to use new AI supercomputer

Mitsui, NVIDIA's Tokyo-1 supercomputer, aims to turbocharge Japan’s use of AI in drug discovery

News

FDA undoes Astellas’ bid for fast review of menopause drug

Pharma company had used a priority review voucher to speed up review of fezolinetant.

News

Naoki Okamura named as next CEO of Astellas

Kenji Yasukawa is stepping down as chief executive of Japanese pharma group Astellas, to be succeeded by Naoki Okamura – currently chief strategy officer – on 1st April.

Astellas cuts $5.9bn deal to buy Iveric Bio

FDA clears Keytruda/Padcev regimen for bladder cancer

Astellas GLOWing as Claudin drug aces gastric cancer trial

Japanese pharmas sign up to use new AI supercomputer

FDA undoes Astellas’ bid for fast review of menopause drug

Naoki Okamura named as next CEO of Astellas

NHS use of digital cardiac rehab tools endorsed

How to meet your physicians where they are online

Astellas

Editor's Picks